06:28 PM EDT, 06/22/2024 (MT Newswires) -- Eli Lilly ( LLY ) said late Friday that its weight-loss drug Zepbound (tirzepatide) was found to benefit obese adults with obstructive sleep apnea in the late-stage Surmount-OSA studies.

Subjects who used the drug saw up to a 52% reduction in obstructive sleep apnea severity, data from the studies showed.

Patients who received tirzepatide also experienced "significant improvements" in systolic blood pressure, hypoxic burden and an inflammation marker known as high-sensitivity C-reactive protein, the company said.